Revance Therapeutics (RVNC) to Offer $150M in Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) announced a proposed underwritten public offering of $150 million of its common stock. In addition, Revance expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The Company intends to use the net proceeds from the offering to fund the commercialization of DAXXIFY™, the RHA® Collection of dermal fillers and OPUL®, and for working capital, research and development and general corporate purposes. The offering is subject to prevailing market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Goldman Sachs & Co. LLC, Cowen and Company, LLC and Guggenheim Securities, LLC are acting as joint book-running managers for the proposed offering. Barclays Capital Inc. is also acting as a bookrunner for the proposed offering.

You May Also Be Interested In

• Goldman Sachs Adjust Monthly US Director's Cut List
• Entrata (ENT) files for proposed IPO
• DeFi Development Corp. plans $20M preferred stock offering